Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 3 1Phase 1 1

Status

Terminated 6Active not recruiting 4Unknown 3Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gynecologic 6

Conditions

Ovarian Neoplasms 5Carcinoma, Ovarian Epithelial 3

Interventions

Cyclophosphamide 389Carboplatin 343Gemcitabine 331pembrolizumab 328Cisplatin 327Paclitaxel 294Radiotherapy 291Docetaxel 285Bevacizumab 249Rituximab 233Capecitabine 221Nivolumab 218Dexamethasone 205Fluorouracil 189fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 133Bortezomib 129fludarabine phosphate 128Cetuximab 126Lenalidomide 125Filgrastim 119Erlotinib Hydrochloride 119Temozolomide 111Radiosurgery 110

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Terminated × Interventional × oregovomab × Clear all
NCT03100006 2022-06-13

ORION-01

National Cancer Centre, Singapore

Phase 1/2 Terminated
13 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

NCT03162562 2020-12-22

The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer

CanariaBio Inc.

Phase 1 Terminated
10 enrolled
Gynecologic

Ovarian Neoplasms

NCT00034138 2007-12-18

A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma

Unither Pharmaceuticals

Phase 1/2 Terminated
24 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00034372 2007-12-18

Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma

Unither Pharmaceuticals

Phase 2 Terminated
102 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00050375 2007-12-18

Clinical Trial for Ovarian Cancer (OvaRex®)

Unither Pharmaceuticals

Phase 3 Terminated
354 enrolled
Gynecologic

Ovarian Neoplasms

NCT00086632 2007-12-18

Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment

Unither Pharmaceuticals

Phase 2 Terminated
40 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡